Lung Macrophage Populations and Functions in Chronic Obstructive Pulmonary Disease (COPD)-Susceptible Smokers
Key facts
- Where
- San Francisco, United StatesSee the 3 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 75 years old?
Source: NCT04722835, who can take part
Where in United States
- San Francisco VA Medical CenterSan Francisco, United StatesTaking people
- University of California San FranciscoSan Francisco, United StatesNo longer taking part
- Zuckerberg San Francisco General Hospital and Trauma CenterSan Francisco, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of California, San Francisco
- Trial code
- NCT04722835
- Record updated
- 4 June 2026
- Original description
Chronic Obstructive Pulmonary Disease (COPD) is a heterogeneous disease that affects only a fraction of those who smoke tobacco. The origin of this variability in susceptibility to develop COPD is unclear, but understanding its underlying biology has important implications for our ability to design suitable preventative and therapeutic strategies for its management. This Department of Defense (DOD) discovery research proposes to develop methodologies and generate preliminary data needed to lay the foundation for a large study that would investigate the underlying biological susceptibility of those who smoke tobacco to develop COPD.Read full original descriptionShow less
Chronic Obstructive Pulmonary Disease (COPD) is a heterogeneous disease that affects only a fraction of those who smoke tobacco. The origin of this variability in susceptibility to develop COPD is unclear, but understanding its underlying biology has important implications for our ability to design suitable preventative and therapeutic strategies for its management. This Department of Defense (DOD) discovery research proposes to develop methodologies and generate preliminary data needed to lay the foundation for a large study that would investigate the underlying biological susceptibility of those who smoke tobacco to develop COPD.
Inclusion: Ages between 40 to 75 years old; History of at least 20 pack-years of smoking; No diagnosis of COPD or asthma; No spirometric evidence of airflow obstruction as determined by FEV1/FVC ratio ≥0.7; FEV1 and FVC >lower limit of normal; Less than 1 pack-year history of tobacco smoking and no tobacco use within the past 12 months; Subjects will be divided into two groups by their RV/TLC:; Normal RV/TLC Group:; Plethysmographic RV/TLC equal or less than lower limit of normal; Abnormal RV/TLC Group:; Plethysmographic RV/TLC higher than lower limit of normal.
Exclusion: Any history of IV drug use or inhalation of recreational drugs other than marijuana: A- within the past 20 years. B- more than 100 times IV drug usage. C- longer than 1 year usage; Serious and active heart conditions- defined by stable or unstable angina, recent myocardial infarction (within the last 2 years), active congestive heart failure, ischemic cardiomyopathy; History of chronic active Hepatitis B or C; Marijuana use >400 joints in lifetime or any within past 6 months; Inability to walk briskly, run on treadmill, or pedal on ergometer to perform the study-required exercise level; Pregnant/breast feeding; Liver cirrhosis.